Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Despite initial concerns that combining pertuzumab and tucatinib would exacerbate severe diarrhea, grade 3 diarrhea increased by only 2% over placebo. Rather than gastrointestinal issues, elevated liver function tests occurred in approximately 25% of patients and served as the leading driver of dose holds, reductions, and treatment discontinuations.

Related Insights

The primary challenge with combining next-gen KRAS inhibitors and immunotherapy is a rapid and severe liver toxicity (transaminitis). A patient's liver function can deteriorate catastrophically in days, demanding vigilant monitoring and specific management protocols that differ between clinical trials.

The HER2CLIMB-02 trial found that adding tucatinib to TDM-1 offered only a modest 2-month PFS benefit. This came at the cost of substantially increased toxicity, including transaminitis and diarrhea, suggesting the two agents are better used sequentially for most patients.

The failure of an adjuvant trial for the TKI pazopanib was likely caused by a protocol change that reduced the dose to manage transaminitis. While well-intentioned to improve tolerability and adherence, the lower dose was sub-therapeutic. This serves as a critical lesson that managing side effects by compromising dose can nullify a drug's potential efficacy.

A critical reason patients stop ADC treatments is the burden of side effects like skin toxicity or GI issues, not just disease progression. This underscores the urgent need to develop ADCs with better safety profiles, enabling patients to stay on effective therapy longer.

Combining KRAS G12C inhibitors with checkpoint inhibitors increases the risk of transaminitis. Differentiating the causative agent is clinically challenging. A rapid recovery after stopping both drugs suggests the KRAS inhibitor is the cause and can be restarted at a lower dose; slower recovery points to the immunotherapy.

A key clinical strategy for managing the TKI Zongertinib is proactive liver function monitoring. Checking AST/ALT every two weeks for the first three months allows clinicians to intervene with dose holds at the first sign of mild elevations, thereby preventing severe toxicity that would mandate a dose reduction.

The combination of the KRAS G12C inhibitor Sotorasib with immunotherapy, a seemingly logical approach, has been abandoned. Clinical trials were closed due to unacceptable levels of hepatotoxicity (liver damage), particularly in patients who had recently received immunotherapy. This demonstrates an unexpected and clinically significant negative drug-drug interaction, serving as a cautionary tale for future combination studies.

For a patient on TDXD plus pertuzumab who develops severe, treatment-limiting diarrhea, a reasonable strategy is to discontinue pertuzumab and continue with TDXD monotherapy. This preserves the most active agent while mitigating toxicity, as the incremental benefit of pertuzumab is not yet reported.

In the LEAP-010 trial, the combination arm's higher efficacy was offset by significantly greater toxicity (67% vs 38% severe adverse events). This increased treatment burden likely limited sustained therapy and prevented patients from receiving subsequent treatments, ultimately nullifying any survival benefit from improved tumor response.

Contrary to the assumption that combinations are more toxic, Lenvatinib/Belzutifan showed a different side effect profile, not a worse one, compared to single-agent Cabozantinib. The combo caused more anemia while Cabozantinib caused more diarrhea and skin toxicity, but treatment discontinuation rates were identical at 11% for both arms.